Replies to post #50636 on Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

Also, K worked synergistically with radiation treatment as well.

"Kevetrin was studied in multiple experiments alone and in conjunction with radiation against the SCC-15 cell line of head and neck cancer. Kevetrin alone showed an average tumor growth delay of 45% compared to controls, similar to radiation alone. When administered in conjunction with radiation, Kevetrin showed an average tumor growth delay of 116%."

And with under colon cancer: "Kevetrin was studied in two experiments alone and in combination with 5-FU against the HT-29 cell line of colon cancer. Kevetrin alone demonstrated average tumor growth delay of 43% compared to controls. 5-FU alone showed an average tumor growth delay of 20%. The combination of Kevetrin and 5-FU resulted in an average tumor growth delay of 97%."

(I edited this post from earlier)

[cabel]

Yes it seems we must educate the masses,.. as it seems we have already hit the jackpot.

Next weeks update will simply confirm what most of us here already know,.. p21 activation at very low doses with no DLT.

[Tails]

Excellent explanation.
And that is why there is a chance we see a partner for K before we have one for P or B.

[Rdunn88]

It would make sense then, for "current owners" of cancer medications to form a partnership with CTIX. Remembering, when Microsoft licensed Windows out to everyone, and not just to IBM. Different sector, but similar strategy. Hopefully, we'll find out next week (partnerships) at the Biotech conference.